Grant: Idea to Innovation
Carleton University
$125,000.00
Next-Generation Bioanalyzer Platform for Saliva and Serum Biomarkers
FY 2024-25
Summary
We are optimizing a novel bioanalyzer platform for determining the concentration of vital biomarkers associated with Alzheimer's Disease (AD), Parkinson's Disease, and Heart Failure (HF) in saliva and serum. The bioanalyzer platform possesses beneficial attributes of rapid response, biomarker selectivity, and feasibility of detecting multiple analytes within the same footprint. Its amperometric response can be directly correlated to biomarker quantities using an electronic reader unit. Detection of cortisol (hormone), dopamine (neurotransmitter) and alpha-synuclein (neuronal protein) in spiked saliva supernatant solutions has already been achieved to show the sensor capabilities in laboratory tests. The device possesses multiplexing capabilities due to the easily translatable and broadly applicable architecture and requires low biofluid volumes for testing (10µL per test). It exhibits excellent limit of detection (LOD: 100 fg/mL) and specificity to target analytes in complex biofluids including saliva and serum. The broad detection range (over seven orders of magnitude) covers the physiological concentration range of target analytes and the label-free sensor read-out is highly suitable for quantifying extremely low concentrations of disease biomarkers for the identified chronic diseases.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
590700-2024
Name nom
Prakash, Ravi R
Department département
Electronics
Organization id
23
Institution établissement
Carleton University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
1702
Research subject group en
Design and manufacturing
Research subject group fr
Conception et fabrication
Research subject en
Advanced manufacturing
Research subject fr
Méthodes de fabrication avancées
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Next-Generation Bioanalyzer Platform for Saliva and Serum Biomarkers
Keywords
alzheimer's disease; amperometric sensors; bio-receptors; electrolyte gated fet; heart failure biomarkers; label-free sensing; multianalyte detection; non-invasive testing; point-of-care; protein aggregation
Application summary
We are optimizing a novel bioanalyzer platform for determining the concentration of vital biomarkers associated with Alzheimer's Disease (AD), Parkinson's Disease, and Heart Failure (HF) in saliva and serum. The bioanalyzer platform possesses beneficial attributes of rapid response, biomarker selectivity, and feasibility of detecting multiple analytes within the same footprint. Its amperometric response can be directly correlated to biomarker quantities using an electronic reader unit. Detection of cortisol (hormone), dopamine (neurotransmitter) and alpha-synuclein (neuronal protein) in spiked saliva supernatant solutions has already been achieved to show the sensor capabilities in laboratory tests. The device possesses multiplexing capabilities due to the easily translatable and broadly applicable architecture and requires low biofluid volumes for testing (10µL per test). It exhibits excellent limit of detection (LOD: 100 fg/mL) and specificity to target analytes in complex biofluids including saliva and serum. The broad detection range (over seven orders of magnitude) covers the physiological concentration range of target analytes and the label-free sensor read-out is highly suitable for quantifying extremely low concentrations of disease biomarkers for the identified chronic diseases.
